Rachel Vatnsdal

Stock Analyst at JP Morgan

(1.12)
# 1891
Out of 5,343 analysts
67
Total ratings
44.19%
Success rate
6.17%
Average return
21 Stocks
Name Action PT Current % Upside Ratings Updated
TXG 10x Genomics
Maintains: Neutral
12 9
8.54 5.39% 4 May 9, 2025
TWST Twist Bioscience
Maintains: Underweight
40 33
28.17 17.15% 2 May 6, 2025
RGEN Repligen
Maintains: Overweight
200 190
120.42 57.78% 6 Apr 29, 2025
RVTY Revvity
Maintains: Neutral
120 100
90.44 10.57% 4 Apr 29, 2025
NVST Envista Holdings
Maintains: Neutral
20 19
16.86 12.69% 4 Mar 6, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
380 390
348.01 12.07% 4 Mar 6, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
50 55
59.33 -7.3% 3 Feb 25, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
50 55
37.08 48.33% 1 Feb 21, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
165 160
109.74 45.8% 6 Nov 26, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
650 670
400.03 67.49% 8 Sep 20, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
88 80
71.32 12.17% 3 Aug 12, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Underweight
17 20
3.94 407.61% 3 Aug 7, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 2 Aug 6, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
1300 1400
1135.42 23.3% 2 Aug 5, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
5 6
8.84 -32.13% 4 Aug 2, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 1 Apr 22, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Overweight
60 90
36.34 147.66% 2 Feb 14, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
250 270
187.44 44.05% 4 Dec 20, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 1 Nov 27, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
90 45
n/a n/a 1 May 22, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Underweight
n/a
n/a n/a 2 Nov 10, 2022